Lilly/Isis Affinitak development dropped
Isis "will not invest further in the development of Affinitak," firm says following failure of second pivotal non-small cell lung cancer trial conducted by partner Lilly. Study investigated the antisense inhibitor in combination with Lilly's Gemzar (gemcitabine) and cisplatin; trial results were to determine fate of drug after failure of first Phase III trial in combination with paclitaxel and carboplatin (1"The Pink Sheet" March 24, 2003, p. 29)...
You may also be interested in...
Lilly will await results from a second Phase III Affinitak study before making a final decision regarding its future role in developing Isis' antisense agent for non-small cell lung cancer
Antoine Marchal, Franchise Head PCR Core Labs - BA Molecular Diagnostics at Qiagen outlines how NeuModx will strengthen its position in the infectious disease space.
Licensing agreements and bolt-on acquisitions to strengthen its R&D pipeline are still in Bayer’s sights as the COVID-19 pandemic and currency devaluations have led to the need for job cuts and substantial cost savings at the big pharma company.